Recommended

Nanoscope signals potential gene therapy advance in retinal disease
Key factors shaping pharmaceutical formulation
ICH opens consultation on Q3E drug impurities guideline
Pharma cautious about direct-to-consumer drug sales
WuXi wins Irish authorisation for biologic manufacturing
Sanofi’s diabetes immunotherapy gains UK first
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
webinar

Navigating the transition from IVDD to IVDR

13 July 2021

Shares

828

This on-demand webinar brings three leaders in the field together to discuss the new regulations, responsibilities across the whole supply chain, documentation, the notified body application process and key timelines.

May 2022 marks a major milestone in the EU’s transition from the In Vitro Diagnostic Directive (IVDD) to the new In Vitro Diagnostic Regulation (IVDR). The new regulations are designed to make all IVD products and devices safer and more reliable, while ensuring the entire supply chain is completely transparent. IVDR will incorporate major technological advances in areas such as next generation sequencing (NGS), point of care diagnostics and personalised medicine, improving the standards of quality to help ensure approved products are safe and stay compliant through a post-marketing surveillance system.

This on-demand webinar brings three leaders in the field together to discuss the new regulations, responsibilities across the whole supply chain, documentation, the notified body application process and key timelines. It highlighted the challenges of the process but also how success can be achieved with strong relationships and co-operation between stakeholders.

This on-demand webinar discussion brings together leading experts to:

  • explain the new rules and responsibilities, the notified body application process, and key dates;
  • highlight current IVDR challenges and bottlenecks facing the industry, and suggest how to mitigate them;
  • draw on experience gained from successful certification applications to give you valuable insights and help you provide your customers with IVDR compliant products following the May 2022 deadline.

Meet our speakers:

Günter WeisshaarGünter Weisshaar, Senior Vice President, Global Head Q&R & Oper. Excellence, Tecan

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Günter joined Tecan in 2003 as Senior Vice President, Head of Quality Assurance and Regulatory Affairs.

He has more than 35 years of experience in the in vitro diagnostics and medical device industry. Together with his team and Tecan’s customers, he ensures successful strategies for commercialisation of products worldwide. Günter is an expert for implementation and certification of quality management systems in medtech and IVD companies (ISO 9001-2015, ISO 13485-2016, QSR 21 CFR 820, IVDR) and a certified enterprise risk manager according to ISO 31000 and ONR 49003.

Günter is also a member of the Regulatory Affairs Committee at EDMA (European Diagnostic Manufacturers Association).

Dr Heike Möhlig-Zuttermeister, Technical Team Manager – IVD, Medical Devices Certification, BSI

Heike has been leading global teams with BSI for seven years.

She combines a wealth of scientific knowledge with over 10 years’ experience in QA and RA, playing a pivotal role in leading multiple high performance teams. She is an established IVD expert and one of the final decision makers for new certifications, positioning her perfectly to oversee the transition from IVDD to IVDR.

Heike was involved in issuing the first IVDR certificates and is a key representative for the European Union Reference Laboratories.

Dr Petra Kaars-WieleDr Petra Kaars-Wiele, Independent Consultant

Petra graduated from the University of Goettingen in Germany with a Diploma in 1980 and with a PhD in 1983. She joined Abbott Laboratories in 1983.
Petra has more than 35 years of experience in regulatory affairs and quality systems for medical devices. She was responsible for all international regulatory matters, medical event reporting, risk management, managing translation for 29 languages and labelling activities at Abbott Diagnostics Division. She has experience in building a Quality Management System (QMS) according 9001 and 13485 and passed lead auditor training in 1997. Since then, she has used that knowledge in training, setting up a QMS or consulting in the field internally and externally.

Petra retired from Abbott in April 2019, after almost 36 years of service, and is now working as an independent consultant.

Her other activities include:

  • Advisor to AHWP Technical Committee
  • Chairwoman of the EDMA Globalization Working Party dealing with new and revised worldwide regulations
  • Member of the EDMA Regulatory Committee and Technical Forum
  • Past Member of the GHTF SG1, IVD Subgroup representing EDMA, from 2003 until 2012
  • Trainer activities for EU Commission, AHWP, ASEAN, APEC and USAID and WHO.
Share via